Seoul National Univ. DMSE
Notice

Seminar & Colloquium

Seminar & Colloquium
[세미나: 11월 10일(목), 오후 4시] Dr. Hyun Jung Kim, Cleveland Clinic

[세미나: 11월 10일(목), 오후 4시] Dr. Hyun Jung Kim, Cleveland Clinic

 

Title

Microengineered Human Gut-on-a-Chip: From Organomimicry to Individualized Precision Medicine

 

Speaker

Dr. Hyun Jung Kim, Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic

 

Education

Harvard University, Boston, MA, USA

- 09/2012 – 12/2014 Wyss Institute for Biologically Inspired Engineering, Technology Development Fellow (Advisor: Donald E. Ingber, MD, PhD)

- 07/2009 – 08/2012 Wyss Institute for Biologically Inspired Engineering, Postdoctoral Fellow (Advisor: Donald E. Ingber, MD, PhD)

The University of Chicago, Department of Chemistry, Chicago, IL, USA

- 03/2007 – 06/2009 Postdoctoral Scholar (Advisor: Rustem F. Ismagilov, PhD)

Yonsei University, Seoul, Republic of Korea 

- 09/2005 – 02/2007 Research Associate, Institute of Life Science and Biotechnology 

- 09/2000 – 08/2005 PhD in Biotechnology (Advisor: Chul Soo Shin, PhD)

- 03/1998 – 08/2000 MS in Biotechnology

- 03/1994 – 02/1998 BE in Biotechnology

 

Professional Experience

- 07/2022 – present  Assistant Staff, Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA

- 01/2015 – 06/2022 Assistant Professor, Department of Biomedical Engineering, Cockrell School of Engineering, The University of Texas at Austin, Austin, TX, USA

- 12/2018 – 06/2022 Assistant Professor, Department of Oncology, Dell Medical School (Courtesy Appointment)

- 03/2018 – 12/2021 Visiting Professor, Department of Medical Engineering, College of Medicine, Yonsei University, Seoul, Republic of Korea

- 09/2015 – 08/2017 Adjunct Professor, School of Medicine, Pusan National University, Yangsan, Republic of Korea

 

| Date | Thursday, November 10th, 2022

 

| Time | 16:00 ~  

 

| Venue | 33동 330호

 

 

[Abstract]

 

The human gut microbiome substantially orchestrates intestinal homeostasis, disease development, and metabolic functions of the human body. Indeed, dysbiosis of human intestinal microbiota develops diverse intestinal disorders that can potentially lead to inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, colorectal cancer (CRC), infectious diseases, or irritable bowel syndrome (IBS) that manifests a dysfunction in the gut-brain axis. However, a lack of robust models of the living human intestine that demonstrates longitudinal host-microbiome crosstalk remains a critical unmet need. Human intestinal organoids have emerged as an advanced tissue-engineered model, but an enclosed lumen embedded in static hydrogel considerably hampers to recapitulate host-microbiome crosstalk in vitro. My group has spearheaded to offer a human Gut-on-a-chip microphysiological model that demonstrates intestinal physiology, three-dimensional (3D) morphogenesis, accurate oxygen control, mechanodynamic bowel movement, and longitudinal host-microbiome co-cultures. The accessibility and modularity of a microengineered Gut-on-a-chip can identify a specific disease trigger by recoupling the uncoupled complex factors germane to disease development in a spatiotemporal manner. In a pathomimetic human intestinal inflammation-on-a-chip model, we discovered that the intact epithelial barrier is necessary and sufficient to maintain the homeostatic tolerance of the gut under complex host-microbiome crosstalks. Furthermore, an integrative culture of patient-derived organoid epithelium in a Gut-on-a-chip enables to simulate patient-specific host responses under various microbial stimulations in an IBD Chip and a CRC Chip. Finally, we highlight the breakthrough of our personalized disease models and discuss the future impact of investigating the etiology and therapeutic targets in multifactorial human gastrointestinal diseases.

 

| Host | 도준상 교수 (880-1605)